CD1D and neoplasm: Other hindrances include reduced expression of CD1d in tumor cells [107], the post-infusion α-GalCer anergy [20], and the long time of process and differentiation of NKT- and autologous DC-cells in a culture medium for adoptive transfer that causes some patients to give up their disease or no longer be eligible for treatment [79].